.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,225,284

« Back to Dashboard
Patent 6,225,284 protects SIGNIFOR LAR and SIGNIFOR and is included in two NDAs.

This patent has thirty-eight patent family members in thirty countries.

Summary for Patent: 6,225,284

Title: Somatostatin peptides
Abstract:Somatostain analogues comprising the amino acid sequence of the formula (I): -(D/L)Trp-Lys-X.sub.1 -X.sub.2, wherein X.sub.1 is a substituted Thr, Ser, Tyr, Glu or Cys residue and X.sub.2 is an .alpha.-amino acid having an aromatic residue on the C.sub..alpha. side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t.-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys.sup.9 of the native somatostatin-14, in free form, in salt form or complexed with a detectable element have interesting pharmacological properties.
Inventor(s): Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bruns; Christian (Freiburg, DE), Chandramouli; Nagarajan (Morristown, NJ), Lewis; Ian (Riehen, CH), Weckbecker; Gisbert (Biel-Benken, CH)
Assignee: Novartis AG (Basle, CH)
Application Number:08/981,426
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 9th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXNo6,225,284► subscribeYY METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXNo6,225,284► subscribeYY METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYes6,225,284► subscribeYY METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,225,284

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9513224Jun 29, 1995
United Kingdom9600429Jan 10, 1996
PCT Information
PCT FiledJune 28, 1996PCT Application Number:PCT/EP96/02840
PCT Publication Date:January 16, 1997PCT Publication Number: WO97/01579

International Patent Family for Patent: 6,225,284

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina004497► subscribe
Austria210152► subscribe
Australia6515096► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc